Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs

Journal of Chemical Information and Modeling

Volumn 54, Issue 9, 2014, Pages 2483-2499

  Feng, Zhiwei ^a   Alqarni, Mohammed Hamed ^a   Yang, Peng ^a   Tong, Qin ^a   Chowdhury, Ananda ^a   Wang, Lirong ^a   Xie, Xiang Qun ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CRYSTAL STRUCTURE; CRYSTALS; METAL IONS; SODIUM; WELL TESTING;

CANNABINOID RECEPTORS; CONFORMATIONAL CHANGE; CRYSTALLOGRAPHIC STRUCTURE; MOLECULAR DYNAMICS SIMULATIONS; NATIONAL CANCER INSTITUTE; SITE-DIRECTED MUTATION; TRANS-MEMBRANE PROTEINS; X RAY CRYSTAL STRUCTURES;

MOLECULAR DYNAMICS;

CANNABINOID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR;

CHEMISTRY; GENETICS; MOLECULAR DYNAMICS; PROTEIN CONFORMATION; SITE DIRECTED MUTAGENESIS; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84916613779     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci5002718     Document Type: Article

References (78)

1. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996.
2. Howlett, A. C. The cannabinoid receptors. Prostaglandins Other Lipid Mediators 2002, 68, 619-631.
3. Mackie, K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 2008, 20, 10-14.
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
5. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 1991, 279, 129-134.
6. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156, 397-411.
7. Feng, R.; Milcarek, C. A.; Xie, X.-Q. Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion. BMC Pharmacol. Toxicol. 2014, 15, 30.
8. Cabral, G. A.; Griffin-Thomas, L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 11, e3.
9. Guindon, J.; Hohmann, A. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 2008, 153, 319-334.
10. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, U.; Essig, J.; Erxlebe, E.; Bab, I.; Kubisch, C.; de Vernejoul, M. C.; Zimmer, A. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet. 2005, 14, 3389-3396.
11. Beltramo, M. Cannabinoid type 2 receptor as a target for chronic - pain. Mini-Rev. Med. Chem. 2009, 9, 11-25.
12. Mbvundula, E. C.; Rainsford, K. D.; Bunning, R. A. Cannabinoids in pain and inflammation. Inflammopharmacology 2004, 12, 99-114.
13. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrié, B.; Rinaldi-Carmona, M.; Calandra, B.; Fur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Eur. J. Biochem. 1996, 237, 704-711.
14. Shoemaker, J. L.; Ruckle, M. B.; Mayeux, P. R.; Prather, P. L. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther. 2005, 315, 828-838.
15. Bisogno, T.; Melck, D.; Bobrov, M.; Gretskaya, N.; Bezuglov, V.; De Petrocellis, L.; Di Marzo, V. N-Acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 2000, 351, 817-824.
16. Song, Z.-H.; Slowey, C.-A.; Hurst, D. P.; Reggio, P. H. The difference between the CB1 and CB2 cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB2. Mol. Pharmacol. 1999, 56, 834-840.
17. Bramblett, R.; Panu, A. M.; Ballesteros, J. A.; Reggio, P. H. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci. 1995, 56, 1971-1982.
18. Gouldson, P.; Calandra, B.; Legoux, P.; Kernéis, A.; Rinaldi- Carmona, M.; Barth, F.; Le Fur, G.; Ferrara, P.; Shire, D. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB2 receptor. Eur. J. Pharmacol. 2000, 401, 17-25.
19. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E. Crystal structure of rhodopsin: AG protein-coupled receptor. Science 2000, 289, 739-745.
20. Krebs, A.; Villa, C.; Edwards, P. C.; Schertler, G. F. Characterisation of an improved two-dimensional p22121 crystal from bovine rhodopsin. J. Mol. Biol. 1998, 282, 991-1003.
21. Xie, X. Q.; Chen, J. Z.; Billings, E. M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins: Struct., Funct., Bioinf. 2003, 53, 307-319.
22. Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
23. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem. 2006, 49, 984-994.
24. Stern, E.; Muccioli, G. G.; Millet, R.; Goossens, J.-F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J.-P. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem. 2006, 49, 70-79.
25. Raduner, S.; Majewska, A.; Chen, J.-Z.; Xie, X.-Q.; Hamon, J.; Faller, B.; Altmann, K.-H.; Gertsch, J. Alkylamides from Echinacea are a new class of cannabinomimetics cannabinoid type 2 receptordependent and-independent immunomodulatory effects. J. Biol. Chem. 2006, 281, 14192-14206.
26. Yang, P.; Myint, K.-Z.; Tong, Q.; Feng, R.; Cao, H.; Almehizia, A. A.; Alqarni, M. H.; Wang, L.; Bartlow, P.; Gao, Y. Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. J. Med. Chem. 2012, 55, 9973-9987.
27. Latek, D.; Kolinski, M.; Ghoshdastider, U.; Debinski, A.; Bombolewski, R.; Plazinska, A.; Jozwiak, K.; Filipek, S. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β2AR. J. Mol. Model. 2011, 17, 2353-2366.
28. Xie, X.-Q.; Chowdhury, A. Advances in methods to characterize ligand-induced ionic lock and rotamer toggle molecular switch in G protein-coupled receptors. Method. Enzymol. 2012, 520, 153-174.
29. Tiburu, E. K.; Tyukhtenko, S.; Deshmukh, L.; Vinogradova, O.; Janero, D. R.; Makriyannis, A. Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. Biochem. Biophy. Res. Commun. 2009, 384, 243-248.
30. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
31. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482, 547-551.
32. Hanson, M. A.; Roth, C. B.; Jo, E.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S. M.; Schuerer, S. C. Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335, 851-855.
33. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, C. G. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 2011, 474, 521-525.
34. Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsujimoto, H.; Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G. W. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011, 475, 65-70.
35. Wang, C.; Wu, H.; Katritch, V.; Han, G. W.; Huang, X.-P.; Liu, W.; Siu, F. Y.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human smoothened receptor bound to an antitumour agent. Nature 2013, 497, 338-343.
36. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehmé, R.; Edwards, P. C.; Leslie, A. G.; Schertler, G. F.; Tate, C. G. The structural basis for agonist and partial agonist action on a β 1- adrenergic receptor. Nature 2011, 469, 241-244.
37. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330, 1066-1071.
38. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V. Structure of the human dopamine D3 receptor in complex with a D2/ D3 selective antagonist. Science 2010, 330, 1091-1095.
39. SYBYL-X 1.3; Tripos International, 1699 South Hanley Rd., St. Louis, Missouri 63144, USA. 2010.
40. Martí-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sánchez, R.; Melo, F.; Šali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
41. Wiederstein, M.; Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007, 35, W407-W410.
42. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
43. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.
44. Yang, P.; Wang, L.; Feng, R.; Almehizia, A. A.; Tong, Q.; Myint, K.-Z.; Ouyang, Q.; Alqarni, M. H.; Wang, L.; Xie, X.-Q. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation. J. Med. Chem. 2013, 56, 2045-2058.
45. Jain, A. N. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J. Comput. Aided-Mol. Des. 1996, 10, 427-440.
46. Chen, J.-Z.; Wang, J.; Xie, X.-Q. GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model. 2007, 47, 1626-1637.
47. Pedretti, A.; Villa, L.; Vistoli, G. VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. J. Mol. Graphics Modell. 2002, 21, 47-49.
48. Søndergaard, C. R.; Olsson, M. H.; Rostkowski, M.; Jensen, J. H. Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J. Chem. Theory Comput. 2011, 7, 2284-2295.
49. Hsin, J.; Arkhipov, A.; Yin, Y.; Stone, J. E.; Schulten, K. Using VMD: an introductory tutorial. Curr. Protoc. Bioinf. 2008, 5.7. 1-5.7. 48.
50. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926.
51. Kalé, L.; Skeel, R.; Bhandarkar, M.; Brunner, R.; Gursoy, A.; Krawetz, N.; Phillips, J.; Shinozaki, A.; Varadarajan, K.; Schulten, K. NAMD2: greater scalability for parallel molecular dynamics. J. Comput. Phys. 1999, 151, 283-312.
52. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
53. MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
54. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A smooth Particle Mesh Ewald method. J. Chem. Phys. 1995, 103, 8577-8593.
55. Prism, G, version 5.01; GraphPad Software Inc.: San Diego, CA, USA, 2007.
56. Lunn, C. A.; Fine, J. S.; Rojas-Triana, A.; Jackson, J. V.; Fan, X.; Kung, T. T.; Gonsiorek, W.; Schwarz, M. A.; Lavey, B.; Kozlowski, J. A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 2006, 316, 780-788.
57. Tandon, M.; Wang, L.; Xu, Q.; Xie, X.; Wipf, P.; Wang, Q. J. A targeted library screen reveals a new inhibitor scaffold for protein kinase d. PloS One 2012, 7, e44653.
58. Aghazadeh Tabrizi, M.; Baraldi, P. G.; Saponaro, G.; Moorman, A.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Tintori, C.; Tuccinardi, T. Discovery of 7-oxo-pyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB2 cannabinoid receptor inverse agonists. J. Med. Chem. 2013, 56, 4482-4496.
59. Kotsikorou, E.; Navas, F., III; Roche, M. J.; Gilliam, A. F.; Thomas, B. F.; Seltzman, H. H.; Kumar, P.; Song, Z.-H.; Hurst, D. P.; Lynch, D. L.; Reggio, P. H. The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)-methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1Hpyrazole- 3-carboxamide (SR144528). J. Med. Chem. 2013, 56, 6593-6612.
60. Kusakabe, K.-i.; Tada, Y.; Iso, Y.; Sakagami, M.; Morioka, Y.; Chomei, N.; Shinonome, S.; Kawamoto, K.; Takenaka, H.; Yasui, K. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. Bioorg. Med. Chem. 2013, 21, 2045-2055.
61. Ashton, J. C.; Wright, J. L.; McPartland, J. M.; Tyndall, J. D. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr. Med. Chem. 2008, 15, 1428-1443.
62. Raitio, K.; Salo, O.; Nevalainen, T.; Poso, A.; Jarvinen, T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem. 2005, 12, 1217-1237.
63. Tao, Q.; McAllister, S. D.; Andreassi, J.; Nowell, K. W.; Cabral, G. A.; Hurst, D. P.; Bachtel, K.; Ekman, M. C.; Reggio, P. H.; Abood, M. E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol. Pharmacol. 1999, 55, 605-613.
64. Shire, D.; Calandra, B.; Delpech, M.; Dumont, X.; Kaghad, M.; Le Fur, G.; Caput, D.; Ferrara, P. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J. Biol. Chem. 1996, 271, 6941-6946.
65. Zhang, Y.; Xie, Z.; Wang, L.; Schreiter, B.; Lazo, J. S.; Gertsch, J.; Xie, X.-Q. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Int. Immunopharmacol. 2011, 11, 1303-1310.
66. Nebane, N. M.; Hurst, D. P.; Carrasquer, C. A.; Qiao, Z.; Reggio, P. H.; Song, Z.-H. Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor. Biochemistry 2008, 47, 13811-13821.
67. Katritch, V.; Abagyan, R. GPCR agonist binding revealed by modeling and crystallography. Trends Pharmacol. Sci. 2011, 32, 637- 643.
68. Salo, O. M.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Järvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem. 2005, 48, 7166- 7171.
69. Rhee, M. H. Functional role of serine residues of transmembrane dopamin VII in signal transduction of CB2 cannabinoid receptor. J. Vet. Sci. 2002, 3, 185-191.
70. Poso, A.; Huffman, J. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br. J. Pharmacol. 2008, 153, 335-346.
71. Kapur, A.; Hurst, D. P.; Fleischer, D.; Whitnell, R.; Thakur, G. A.; Makriyannis, A.; Reggio, P. H.; Abood, M. E. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol. 2007, 71, 1512-1524.
72. Fenalti, G.; Giguere, P. M.; Katritch, V.; Huang, X.-P.; Thompson, A. A.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Molecular control of [dgr]-opioid receptor signalling. Nature 2014, 506, 191-196.
73. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; IJzerman, A. P. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012, 337, 232-236.
74. Howard, M. J.; Hughes, R. J.; Motulsky, H. J.; Mullen, M. D.; Insel, P. A. Interactions of amiloride with alpha-and beta-adrenergic receptors: amiloride reveals an allosteric site on alpha 2-adrenergic receptors. Mol. Pharmacol. 1987, 32, 53-58.
75. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Abood, M. E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 2009, 284, 29817- 29827.
76. Feng, Z.; Hou, T.; Li, Y. Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations. J. Chem. Inf. Model. 2012, 52, 1005-1014.
77. Rasmussen, S. G.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477, 549-555.
78. Li, J.; Jonsson, A. L.; Beuming, T.; Shelley, J. C.; Voth, G. A. Ligand-dependent activation and deactivation of the human adenosine A2A receptor. J. Am. Chem. Soc. 2013, 135, 8749-8759.